Published in Saudi J Gastroenterol on July 19, 2017
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Tissue destruction by neutrophils. N Engl J Med (1989) 13.81
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology (2000) 5.40
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology (1999) 4.41
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med (1996) 4.11
Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology (1993) 3.98
A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med (1995) 3.98
The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med (1995) 3.94
Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype. J Clin Pathol (1995) 3.86
Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol (1995) 2.12
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology (1997) 1.56
Safety of the long-term use of proton pump inhibitors. World J Gastroenterol (2010) 1.55
Who is using chronic acid suppression therapy and why? Am J Gastroenterol (2003) 1.34
Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter (2000) 1.12
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut (1997) 1.07
Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion (2001) 1.04
Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion (1992) 1.04
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther (1998) 0.99
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther (2006) 0.98
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther (1993) 0.91
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther (2001) 0.88
Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep (2008) 0.88
Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers. Scand J Gastroenterol (2010) 0.86
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Aliment Pharmacol Ther (2001) 0.84
Distribution of atrophy in Helicobacter pylori-infected subjects taking proton pump inhibitors. Scand J Gastroenterol (2000) 0.84
Long-term management of GERD in the elderly with pantoprazole. Clin Interv Aging (2007) 0.79
Pantoprazole in severe acid-peptic disease: the effectiveness and safety of 5 years' continuous treatment. Dig Liver Dis (2005) 0.78
A program to compute the generalized Mantel-Haenszel chi-square for multiple 2 x J tables. Comput Programs Biomed (1984) 0.78